title: How omalizumab came to be studied as a therapy for chronic spontaneous/idiopathic urticaria.
authors.affiliation: Department of Medicine, Medical University of South Carolina, Charleston, SC.
authors.forename: Allen P
authors.initials: AP
authors.lastname: Kaplan
authors.affiliation: Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC. Electronic address: josephk@musc.edu.
authors.forename: Kusumam
authors.initials: K
authors.lastname: Joseph
authors.affiliation: Department of Medicine, Johns Hopkins University, Baltimore, Md.
authors.forename: Sarbjit S
authors.initials: SS
authors.lastname: Saini
mesh_terms: D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology*; D000069444:Omalizumab / Q000627:therapeutic use*
chemical_list: D018926:Anti-Allergic Agents; D018927:Anti-Asthmatic Agents; D000069444:Omalizumab; D007073:Immunoglobulin E